糖尿病合并晚期非透析慢性肾脏病患者的肾素-血管紧张素-醛固酮系统阻断治疗:系统评价与荟萃分析
该系统评价与荟萃分析纳入9项随机对照试验(n=9797),评估糖尿病合并CKD 3-5期非透析患者使用RAAS阻断剂的效果。结果显示RAAS阻断剂未显著降低全因死亡率或心血管死亡率,但复合终点(需RRT或血清肌酐翻倍)风险显著降低(RR=0.81)。
要点
- RAAS阻断剂未显著改善糖尿病合并CKD 3-5期患者的全因死亡率(RR=0.97,95%CI 0.85-1.10)。
- 未发现RAAS阻断剂加速此类患者进入RRT的证据。
核心结论
- 在糖尿病合并CKD 3-5期非透析患者中,RAAS阻断剂未带来明确的生存获益,但对肾脏复合终点有有利影响。
- 未发现RAAS阻断剂加速需要RRT的证据。
研究设计与样本
- 系统评价与荟萃分析,纳入9项随机对照试验,共9797例糖尿病合并CKD 3-5期非透析成人患者。
- 试验时长至少6个月,比较单种RAAS阻断剂与安慰剂或其他降压药。
主要发现
- 全因死亡率无差异:RR=0.97(95%CI 0.85-1.10)。
- 心血管死亡率无差异:RR=1.03(95%CI 0.75-1.41)。
- 不良事件无差异:RR=1.05(95%CI 0.89-1.25)。
- 非致死性心血管事件呈有利趋势:RR=0.90(95%CI 0.81-1.00)。
- 需RRT或血清肌酐翻倍的复合终点风险降低:RR=0.81(95%CI 0.70-0.92)。
关键数值与推荐
- 全因死亡率RR=0.97(95%CI 0.85-1.10)。
- 心血管死亡率RR=1.03(95%CI 0.75-1.41)。
- 需RRT或血清肌酐翻倍复合终点RR=0.81(95%CI 0.70-0.92)。
- 非致死性心血管事件RR=0.90(95%CI 0.81-1.00)。
- 不良事件RR=1.05(95%CI 0.89-1.25)。
临床怎么用
- 对于糖尿病合并CKD 3-5期非透析患者,使用RAAS阻断剂可能延缓肾脏复合终点,但需权衡缺乏生存获益。
- 不应因担心加速RRT而避免使用RAAS阻断剂,因证据未显示该风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The presumed superiority of renin-angiotensin-aldosterone system (RAAS)-blocking agents over other antihypertensive agents in patients with diabetes to delay development of end-stage kidney disease (ESKD) has recently been challenged. In addition, there is ongoing uncertainty whether RAAS-blocking agents reduce mortality and/or delay ESKD in patients with diabetes and chronic kidney disease (CKD) stages 3-5. In this subgroup, there might be an expedited need for renal replacement therapy (RRT) when RAAS-blocking agents are used. We conducted a meta-analysis of randomized controlled trials (RCTs) of at least 6-months duration in adult patients with diabetes who also have non-dialysis CKD stages 3-5. RCTs comparing single RAAS-blocking agents to placebo or alternative antihypertensive agents were included. Outcomes of interest were all-cause mortality, cardiovascular morbidity, progression of renal function, ESKD and adverse events. A total of nine trials (n = 9797 participants with CKD stages 3-5) fit our inclusion criteria. There was no difference between the RAAS group and control group regarding all-cause mortality {relative risk [RR] = 0.97 [95% confidence interval (CI) 0.85-1.10]}, cardiovascular mortality [RR = 1.03 (95% CI 0.75-1.41)] and adverse events [RR = 1.05 (95% CI 0.89-1.25)]. There was a trend for a favourable effect for non-fatal cardiovascular events [RR = 0.90 (95% CI 0.81-1.00)] and a lower risk of the composite endpoint need for RRT/doubling of serum creatinine [RR = 0.81 (95% CI 0.70-0.92)] in the RAAS-blocking agents group versus the control group. We found evidence that in patients with diabetes mellitus and CKD stages 3-5, treatment with RAAS-blocking agents did not result in a clear survival advantage. The effect on renal outcomes did depend on the selected outcome measure. However, we did not find evidence that the use of RAAS-blocking agents expedited the need for RRT in patients with CKD stages 3-5.
引用
- Nistor I, De Sutter J, Drechsler C, et al. Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018. PMID: 29106631. doi:10.1093/ndt/gfx072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。